Trial · NCT03409744
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216 | Overall Study Total Evinacumab | Participants with any TEAE | 93 | Number of participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216 | Overall Study Total Evinacumab | Participants with at least one serious TEAE | 27 | Number of participants | |
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Over Time | Overall Study Total Evinacumab | Week 8 | -46.45 | Standard Deviation 35.504 | Percentage of change |
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Over Time | Overall Study Total Evinacumab | Week 24 | -43.64 | Standard Deviation 37.606 | Percentage of change |
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Over Time | Overall Study Total Evinacumab | Week 48 | -43.88 | Standard Deviation 36.037 | Percentage of change |
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Over Time | Overall Study Total Evinacumab | Week 72 | -45.17 | Standard Deviation 31.571 | Percentage of change |
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Over Time | Overall Study Total Evinacumab | Week 96 | -38.00 | Standard Deviation 52.859 | Percentage of change |
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Over Time | Overall Study Total Evinacumab | Week 120 | -33.10 | Standard Deviation 65.888 | Percentage of change |
| Absolute Change in LDL-C Over Time | Overall Study Total Evinacumab | Week 8 | -142.1 | Standard Deviation 114.61 | mg/dL |
| Absolute Change in LDL-C Over Time | Overall Study Total Evinacumab | Week 24 | -132.0 | Standard Deviation 124.37 | mg/dL |
| Absolute Change in LDL-C Over Time | Overall Study Total Evinacumab | Week 48 | -132.8 | Standard Deviation 133.29 | mg/dL |
| Absolute Change in LDL-C Over Time | Overall Study Total Evinacumab | Week 72 | -135.1 | Standard Deviation 121.91 | mg/dL |
| Absolute Change in LDL-C Over Time | Overall Study Total Evinacumab | Week 96 | -131.4 | Standard Deviation 129.29 | mg/dL |
| Absolute Change in LDL-C Over Time | Overall Study Total Evinacumab | Week 120 | -132.5 | Standard Deviation 132.03 | mg/dL |
| Percent Change in Apolipoprotein B (Apo B) Over Time | Overall Study Total Evinacumab | Week 8 | -39.74 | Standard Deviation 25.338 | Percentage of change |
| Percent Change in Apolipoprotein B (Apo B) Over Time | Overall Study Total Evinacumab | Week 24 | -36.98 | Standard Deviation 27.574 | Percentage of change |
| Percent Change in Apolipoprotein B (Apo B) Over Time | Overall Study Total Evinacumab | Week 48 | -35.85 | Standard Deviation 29.998 | Percentage of change |
| Percent Change in Apolipoprotein B (Apo B) Over Time | Overall Study Total Evinacumab | Week 72 | -37.60 | Standard Deviation 27.292 | Percentage of change |
| Percent Change in Apolipoprotein B (Apo B) Over Time | Overall Study Total Evinacumab | Week 96 | -32.54 | Standard Deviation 39.969 | Percentage of change |
| Percent Change in Apolipoprotein B (Apo B) Over Time | Overall Study Total Evinacumab | Week 120 | -27.73 | Standard Deviation 51.722 | Percentage of change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03409744/results